We are proud to be supporting @touchbbca at their Magic Touch #Anniversary Celebration on Sunday, September 19. Learn more about this event & join us in recognizing TOUCH’s ongoing efforts in building a movement to eradicate #BlackBreastCancer: https://t.co/YroAXc1FDE
Evidence of anti-tumor activity w/ #AbscopalEffect from our Phase II #Melanoma program data paved the way for the expansion of our #ImmunoOncologyPipeline, including a study designed to test our platform technology in #TNBC. Learn more: https://t.co/pNSr99yoFO
This August, join us in recognizing #SummerSunSafetyMonth by taking the precautions necessary to protect your skin from the sun to prevent #SkinCancer. Click here to learn how you can reduce exposure to the sun and minimize your risk: https://t.co/lsGNHqPruK
OncoSec is committed to delivering safer and more effective #cancer treatments that can provide long-term benefits for patients. Learn more about our #ExpandedAccessProgram here: https://t.co/ihyInQTLM3
Our #DNA gene transfer technology is being studied in pivotal Phase II trials in #MetastaticMelanoma. Recent results have demonstrated a local #Immune response as either a #Monotherapy or a #CombinationTreatment approach. Learn more here: https://t.co/nLUlzA5j6I
#DYK most solid tumors treated with anti-PD-1/PD-L1 therapies do not respond to treatment? This is one of the greatest challenges in #Oncology today. Our Phase II results are pacing the way for the growth of our #ImmunoOncology#Pipeline. Learn more: https://t.co/VCcRYS1c69
This July, join us in recognizing #UVSafetyAwarenessMonth by taking the right precautions to enjoy the sun & outdoors this #summer while protecting yourself to #PreventCancer. Learn more about ways you can minimize the risk that comes with sun exposure: https://t.co/MFl2By3FWo
We are pleased to announce that we have entered into a collaboration agreement with @Merck for a pivotal global #Phase3 study, KEYNOTE-687 for late-stage #MetastaticMelanoma. Learn more here: https://t.co/05fLprhLrU
Our Chief Scientific Officer, Dr. Christopher Twitty, is presenting information on the amplification of the CXR3/CXCL9 axis via #intratumoral#electroporation at the @Oxford Global Conferences #ImmunoWeek being held from July 6-9. For more details: https://t.co/frPzCr3XVn
Our CEO, Dan O’Connor, Our Chief Clinical Development Officer, Sandra Aung, PhD & our Strategic Clinical Advisor, Alain Algazi, MD, will be presenting at the @RaymondJames Human Health Innovation #Conference on Monday, June 21. Check it out here: https://t.co/pZhWro3Rx2
We are thrilled to welcome Jeffrey Silverman as Vice President of Product Engineering to the OncoSec team. Learn more about his extensive industry experience in the manufacturing of #MedicalDevices including #electroporation equipment & more: https://t.co/lxHv8g0xVH
Yesterday was #NationalCancerSurvivorsDay. We proudly recognize this day that provides an opportunity for people living with a history of cancer to connect, celebrate #milestones, raise #awareness of the ongoing challenges cancer survivors face, & more: https://t.co/e3RF4VRG4i
Our CEO, Dan O’Connor, has been selected as a #finalist for the #EntrepreneurOfTheYear 2021 New Jersey #Award by @EYnews. This is one of the preeminent competitive business awards for entrepreneurs & leaders of high-growth companies. Learn more here: https://t.co/BD9noePB0D
Our CEO, Dan O’Connor, will be participating in a #FiresideChat with the @MaximGrp this morning at 11:00am ET. Don’t miss out and register for the event here: https://t.co/xM9Ms9nGK5